12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ozurdex dexamethasone intravitreal implant regulatory update

The Scottish Medicines Consortium again recommended against the use of Allergan's Ozurdex dexamethasone intravitreal implant on the National Health Service (NHS) in Scotland to treat macular edema following either branch retinal vein occlusion (BRVO) or central vein occlusion (CRVO) in adults. The consortium reiterated...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >